Selection of antiresorptive or anabolic treatments for postmenopausal osteoporosis

Nature Clinical Practice Endocrinology and Metabolism

Volumn 4, Issue 9, 2008, Pages 514-523

  Papapoulos, Socrates ^a   Makras, Polyzois ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Bisphosphonates; Bone turnover; Fractures; Osteoporosis; Parathyroid hormone

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCIUM; DEOXYPYRIDINOLINE; ESTROGEN; PARATHYROID HORMONE; PARATHYROID HORMONE[1-34]; RECOMBINANT PARATHYROID HORMONE; RISEDRONIC ACID; SELECTIVE ESTROGEN RECEPTOR MODULATOR; VITAMIN D;

BONE DENSITY; BONE TURNOVER; CLINICAL ASSESSMENT; COST EFFECTIVENESS ANALYSIS; DRUG SAFETY; DRUG TOLERABILITY; DUAL ENERGY X RAY ABSORPTIOMETRY; HUMAN; OSSIFICATION; OSTEOLYSIS; PATHOPHYSIOLOGY; POST HOC ANALYSIS; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK FACTOR; VERTEBRA FRACTURE;

ANABOLIC AGENTS; BONE AND BONES; BONE DENSITY CONSERVATION AGENTS; BONE REMODELING; DRUG COMBINATIONS; HUMANS; OSTEOPOROSIS, POSTMENOPAUSAL; PATIENT SELECTION;

EID: 50049105974     PISSN: 17458366     EISSN: 17458374     Source Type: Journal    
DOI: 10.1038/ncpendmet0941     Document Type: Review

References (76)

1. Kanis JA (1994) Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: synopsis of a WHO report. WHO Study Group. Osteoporos Int 4: 368-381
2. Bouxsein ML (2005) Determinants of skeletal fragility. Best Pract Res Clin Rheumatol 19: 897-911
3. Seeman E and Delmas PD (2006) Bone quality - the material and structural basis of bone strength and fragility. N Engl J Med 354: 2250-2261
4. Felsenberg D and Boonen S (2005) The bone quality framework: determinants of bone strength and their interrelationships, and implications for osteoporosis management. Clin Ther 27: 1-11
5. Manolagas SC (2000) Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis. Endocr Rev 21: 115-137
6. Parfitt AM (2001) Skeletal heterogeneity and the purpose of bone remodeling; implications for the understandimg of osteoporosis. In Osteoporosis, 433-447 (Eds Marcus R et al.) San Diego: Academic Press
7. Viguet-Carrin S et al. (2006) The role of collagen in bone strength. Osteoporos Int 17: 319-336
8. Recker R et al. (2004) Bone remodeling increases substantially in the years after menopause and remains increased in older osteoporosis patients. J Bone Miner Res 19: 1628-1633
9. Whyte MP et al. (1982) Postmenopausal osteoporosis. A heterogeneous disorder as assessed by histomorphometric analysis of iliac crest bone from untreated patients. Am J Med 72: 193-202
10. Arlot ME et al. (1990) Trabecular and endocortical bone remodeling in postmenopausal osteoporosis: comparison with normal postmenopausal women. Osteoporos Int 1: 41-49
11. Eriksen EF et al. (1990) Cancellous bone remodeling in type I (postmenopausal) osteoporosis: quantitative assessment of rates of formation, resorption, and bone loss at tissue and cellular levels. J Bone Miner Res 5: 311-319
12. Bone HG et al. (2004) Ten years' experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 350: 1189-1199
13. Delmas PD (2000) How does antiresorptive therapy decrease the risk of fracture in women with osteoporosis? Bone 27: 1-3
14. Hochberg MC et al. (2002) Changes in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents. J Clin Endocrinol Metab 87: 1586-1592
15. Bauer DC et al. (2004) Change in bone turnover and hip, non-spine, and vertebral fracture in alendronate-treated women: the fracture intervention trial. J Bone Miner Res 19: 1250-1258
16. Eastell R et al. (2003) Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate. J Bone Miner Res 18: 1051-1056
17. Sarkar S et al. (2004) Relationship between changes in biochemical markers of bone turnover and BMD to predict vertebral fracture risk. J Bone Miner Res 19: 394-401
18. Bjarnason NH et al. (2001) Six and twelve month changes in bone turnover are related to reduction in vertebral fracture risk during 3 years of raloxifene treatment in postmenopausal osteoporosis. Osteoporos Int 12: 922-930
19. Boivin GY et al. (2000) Alendronate increases bone strength by increasing the mean degree of mineralization of bone tissue in osteoporotic women. Bone 27: 687-694
20. Roschger P et al. (2001) Alendronate increases degree and uniformity of mineralization in cancellous bone and decreases the porosity in cortical bone of osteoporotic women. Bone 29: 185-191
21. Borah B et al. (2006) Long-term risedronate treatment normalizes mineralization and continues to preserve trabecular architecture: sequential triple biopsy studies with micro-computed tomography. Bone 39: 345-352
22. Roschger P et al. (2007) Mineralization status of bone matrix in postmenopausal women during a 10-year alendronate treatment period. J Bone Miner Res 22 (suppl 1): S129
23. Recker R et al. (2005) Trabecular bone microarchitecture after alendronate treatment of osteoporotic women. Curr Med Res Opin 21: 185-194
24. Borah B et al. (2004) Risedronate preserves bone architecture in postmenopausal women with osteoporosis as measured by three-dimensional microcomputed tomography. Bone 34: 736-746
25. Plotkin LI et al. (2006) Dissociation of the pro-apoptotic effects of bisphosphonates on osteoclasts from their anti-apoptotic effects on osteoblasts/osteocytes with novel analogs. Bone 39: 443-452
26. Wells GA et al. (2008) Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database of Systematic Reviews 2008, Issue 1. Art. No.: CD001155. [doi:10.1002/14651858.CD001155.pub2]
27. Wells G et al. (2008) Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database of Systematic Reviews 2008, Issue 1. Art. No.: CD004523. [doi:10.1002/14651858.CD004523.pub3]
28. Nguyen ND et al. (2006) Anti-hip fracture efficacy of biophosphonates: a Bayesian analysis of clinical trials. J Bone Miner Res 21: 340-349
29. Black DM et al. (2007) Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 356: 1809-1822
30. Cranney A et al. Ibandronate for the prevention of non-vertebral fractures: a pooled analysis of individual patient data. Osteoporos Int, in press
31. McClung MR et al. (2005) Opposite bone remodeling effects of teriparatide and alendronate in increasing bone mass. Arch Intern Med 165: 1762-1768
32. Bauer DC et al. (2006) Short-term changes in bone turnover markers and bone mineral density response to parathyroid hormone in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 91: 1370-1375
33. Compston JE (2007) Skeletal actions of intermittent parathyroid hormone: effects on bone remodelling and structure. Bone 40: 1447-1452
34. Hodsman AB and Steer BM (1993) Early histomorphometric changes in response to parathyroid hormone therapy in osteoporosis: evidence for de novo bone formation on quiescent cancellous surfaces. Bone 14: 523-527
35. Lindsay R et al. (2006) A novel tetracycline labeling schedule for longitudinal evaluation of the short-term effects of anabolic therapy with a single iliac crest bone biopsy: early actions of teriparatide. J Bone Miner Res 21: 366-373
36. 1-34 on bone formation on cancellous, endocortical, and periosteal surfaces of the human ilium. J Bone Miner Res 22: 495-502
37. Arlot M et al. (2005) Differential effects of teriparatide and alendronate on bone remodeling in postmenopausal women assessed by histomorphometric parameters. J Bone Miner Res 20: 1244-1253
38. Fox J et al. (2005) Treatment of postmenopausal osteoporotic women with parathyroid hormone 1-84 for 18 months increases cancellous bone formation and improves cancellous architecture: a study of iliac crest biopsies using histomorphometry and micro computed tomography. J Musculoskelet Neuronal Interact 5: 356-357
39. Dempster DW et al. (2001) Effects of daily treatment with parathyroid hormone on bone microarchitecture and turnover in patients with osteoporosis: a paired biopsy study. J Bone Miner Res 16: 1846-1853
40. 1-34 [teriparatide] improves both cortical and cancellous bone structure. J Bone Miner Res 18: 1932-1941
41. Misof BM et al. (2003) Effects of intermittent parathyroid hormone administration on bone mineralization density in iliac crest biopsies from patients with osteoporosis: a paired study before and after treatment. J Clin Endocrinol Metab 88: 1150-1156
42. Paschalis EP et al. (2005) Bone mineral and collagen quality in iliac crest biopsies of patients given teriparatide: new results from the fracture prevention trial. J Clin Endocrinol Metab 90: 4644-4649
43. 1-34 on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344: 1434-1441
44. 1-84 on vertebral fracture and bone mineral density in postmenopausal women with osteoporosis: a randomized trial. Ann Intern Med 146: 326-339
45. Siris ES et al. (2001) Identification and fracture outcomes of undiagnosed low bone mineral density in postmenopausal women: results from the National Osteoporosis Risk Assessment. JAMA 286: 2815-2822
46. Schuit SC et al. (2004) Fracture incidence and association with bone mineral density in elderly men and women: the Rotterdam Study. Bone 34: 195-202
47. Kanis JA et al. (2002) A new approach to the development of assessment guidelines for osteoporosis. Osteoporos Int 13: 527-536
48. de Laet CE et al. (1997) Bone density and risk of hip fracture in men and women: cross sectional analysis. BMJ 315: 221-225
49. Kanis JA et al. (2004) A family history of fracture and fracture risk: a meta-analysis. Bone 35: 1029-1037
50. Kanis JA et al. (2004) A meta-analysis of previous fracture and subsequent fracture risk. Bone 35: 375-382
51. Kanis JA et al. (2005) Smoking and fracture risk: a meta-analysis. Osteoporos Int 16: 155-162
52. Kanis JA on behalf of the World Health Organization Scientific Group (2007) Assessment of osteoporosis at the primary health-care level. Technical Report. Sheffield: WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield
53. Kanis JA et al. (2008) FRAX™ and the assessment of fracture probability in men and women from the UK. Osteoporos Int 19: 385-397
54. Garnero P et al. (1996) Markers of bone resorption predict hip fracture in elderly women: the EPIDOS Prospective Study. J Bone Miner Res 11: 1531-1538
55. Van Daele PL et al. (1996) Case-control analysis of bone resorption markers, disability, and hip fracture risk: the Rotterdam study. BMJ 312: 482-483
56. Civitelli R et al. (1988) Bone turnover in postmenopausal osteoporosis. Effect of calcitonin treatment. J Clin Invest 82: 1268-1274
57. Gonnelli S et al. (1997) The usefulness of bone turnover in predicting the response to transdermal estrogen therapy in postmenopausal osteoporosis. J Bone Miner Res 12: 624-631
58. Gonnelli S et al. (1999) Bone turnover and the response to alendronate treatment in postmenopausal osteoporosis. Calcif Tissue Int 65: 359-364
59. Seibel MJ et al. (2004) Relationship between pretreatment bone resorption and vertebral fracture incidence in postmenopausal osteoporotic women treated with risedronate. J Bone Miner Res 19: 323-329
60. Bauer DC et al. (2006) Pretreatment levels of bone turnover and the antifracture efficacy of alendronate: the fracture intervention trial. J Bone Miner Res 21: 292-299
61. Chen P et al. (2005) Early changes in biochemical markers of bone formation predict BMD response to teriparatide in postmenopausal women with osteoporosis. J Bone Miner Res 20: 962-970
62. Delmas PD et al. (2006) Fracture risk reduction during treatment with teriparatide is independent of pretreatment bone turnover. Bone 39: 237-243
63. Black DM et al. (2003) The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med 349: 1207-1215
64. Finkelstein JS et al. (2003) The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. N Engl J Med 349: 1216-1226
65. Deal C et al. (2005) Combination teriparatide and raloxifene therapy for postmenopausal osteoporosis: results from a 6-month double-blind placebo-controlled trial. J Bone Miner Res 20: 1905-1911
66. Ettinger B et al. (2004) Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate. J Bone Miner Res 19: 745-751
67. McCloskey E et al. (2007) Effects of prior antiresorptive therapy on the bone mineral density response to two years of teriparatide treatment in postmenopausal women with osteoporosis: final results from the EUROFORS trial. Calcif Tissue Int 80 (suppl 1): s30
68. Cosman F et al. (1998) Alendronate does not block the anabolic effect of PTH in postmenopausal osteoporotic women. J Bone Miner Res 13: 1051-1055
69. Obermaier-Pietsch CB et al. (2007) Effects of prior antiresorptive therapy on markers of bone formation after 6 months of teriparatide treatment in postmenopausal women with osteoporosis: results from the Eurofors trial. Calcif Tissue Int 80 (suppl 1): s137
70. Delmas P et al. (2007) Bone turnover markers demonstrate greater earlier responsiveness to teriparatide following treatment with risedronate compared with alendronate: the OPTAMISE study. J Bone Miner Res 22 (suppl 1): S27
71. 1-84 for osteoporosis. N Engl J Med 353: 555-565
72. Rittmaster RS et al. (2000) Enhancement of bone mass in osteoporotic women with parathyroid hormone followed by alendronate. J Clin Endocrinol Metab 85: 2129-2134
73. 1-34]. Osteoporos Int 15: 992-997
74. Lindsay R et al. (2004) Sustained vertebral fracture risk reduction after withdrawal of teriparatide in postmenopausal women with osteoporosis. Arch Intern Med 164: 2024-2030
75. Kaufman JM et al. (2005) Teriparatide effects on vertebral fractures and bone mineral density in men with osteoporosis: treatment and discontinuation of therapy. Osteoporos Int 16: 510-516
76. Papapoulos SE (1996) Bisphosphonates: pharmacology and use in the treatment of osteoporosis. In Osteoporosis, 1209-1233 (Eds Marcus R et al.) New York, NY: Academic Press